Economic profileVenlafaxine XL versus diazepam

Study & countryLimitationsApplicabilityOther commentsIncremental cost (£)1Incremental effectICER (£/effect)1Uncertainty1
Guest et al., 2004
UK
Potentially serious limitations2Partially applicable3
  • Measure of outcome: percentage of people with successful treatment defined as CGI score of 1 at 6 months
  • Time horizon: 6 months
£5610.8% extra successfully treated people£516/successfully treated personVenlafaxine XL dominates − £2,203/successfully treated person
Probabilistic analysis: venlafaxine XL dominated diazepam in at least 25% of iterations
1

Costs uplifted to 2009 UK pounds using the UK HCHS inflation index.

2

Efficacy data derived selectively from one RCT; resource use estimated based on expert opinion; limited sensitivity analysis; funded by industry

3

UK/NHS perspective; no QALYs estimated but outcome measure considered relevant; utility scores for GAD are still scarce and of low quality

From: Appendix 18, GRADE evidence profiles

Cover of Generalised Anxiety Disorder in Adults
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care.
NICE Clinical Guidelines, No. 113.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.